Skip to main content

Table 1 Baseline characteristics of subjects

From: Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease

Variable

Control group

PCI group

CABG group

N

47

64

57

Age (year)

63.17 ± 8.34

62.13 ± 9.81

65 ± 8.34

Gender

M 54.55%, F 45.45%

M 56.25%, F 43.75%

M 52.63%, F 47.37%

LVEF

60.32 ± 8.63%

57.62 ± 10.27%

59.48 ± 10.27%

BMI

27.35 ± 1.65

27.83 ± 1.83

28.47 ± 1.93

CrCl

75.71 ± 9.55

73.83 ± 15.27

74.64 ± 9.23

TC mmol/L

5.47 ± 1.25

5.34 ± 0.97

TG mmol/l

1.83 ± 0.89

1.68 ± 0.56

LDL-c mmol/l

3.5 ± 0.93

3.42 ± 0.81

Aspirin

97%

98%

96%

Statin

88%

92%

89%

CCB

55%

33%

35%

ACEI

55%

70%

67%

BB

77%

81%

83%

Other

20%

33%

37%

  1. ACEi angiotensin convertase enzyme inhibitor, BB beta blockers, BMI body mass index, CCB calcium channel blocator, CrCrl creatinine clearance, F female, Gal-3 galectin-3, LVEF left ventricular ejection fraction, M male, TC total cholesterol, TG triglycerides. Other drugs that do not have IA level of evidence in treatment of stable coronary heart disease, mainly symptomatic therapy (long-acting nitrates, trimetazidime)